To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.
Initiator PharmInitiator Pharma har genomfört den första doseringen i den omstartade Fas I studien med IPED2015
Initiator Pharma A/S, ett biotechbolag som utvecklar en ny behandling av erektil dysfunktion meddelade i dag att man har genomfört den första doseringen i den omstartade Fas I studien.
Initiator Pharma has completed first dosing of the re-started Phase I study with IPED2015
Initiator Pharma A/S, a biotech company that is developing a novel treatment of erectile dysfunction today announced that it has completed first dosing of the re-started Phase I study.
Delårsrapport för kv 3 2018
Finansiella höjdpunkter Initiator Pharma A/S är ett danskt företag och upprättar sina finansiella räkenskaper i danska kronor (DKK). Initiator Pharma A/S registrerades den 2 maj 2016….
Q3 report 2018
Financial Highlights Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK). Initiator Pharma A/S was registered on May 2, 2016….
Initiator Pharma meddelar att nyttjande av teckningsoptioner och riktad nyemission registrerat hos Erhvervsstyrelsen
Initiator Pharma A/S (“Initiator Pharma”) meddelar idag, den 15 november 2018, att nyttjandet av bolagets teckningsoptioner av serie TO 1, vars nyttjandeperiod avslutades den 1 november 2018, samt den genomförda riktade nyemissionen, nu har registrerats hos Erhvervsstyrelsen.
Initiator Pharma announces that exercised warrants and directed share issue are now registered with the Danish Companies Registration Office
Initiator Pharma A/S (“Initiator Pharma”) announced today, November 15, 2018, that the exercised series TO 1 warrants, whose subscription period ended on November 1, 2018, and the directed share issue, have now been registered with the Danish Companies Registration Office.
Initiator Pharma sluter optionsavtal för Fas 2 redo läkemedelskandidat
Initiator Pharma A/S, ett biotekbolag som utvecklar en ny behandling av erektil dysfunktion meddelar i dag att man har slutit ett optionsavtal med Saniona AB, avseende en Fas 2 klar läkemedelskandidat.
Initiator Pharma signs option agreement for Phase 2 ready drug candidate
Initiator Pharma A/S, a biotech company that is developing a novel treatment of erectile dysfunction today announced that it has signed an option agreement with Saniona AB, for a phase 2 ready drug candidate.
Initiator Pharma is allocated approximately SEK 12.7 million through exercise of warrants and directed share issue
On November 1st, 2018, the exercise period for series TO 1 warrants in Initiator Pharma A/S (“Initiator Pharma”) ended. In total, 5.462.843warrants of series TO 1 were exercised, which means a subscription rate of 94,4 percent.In order for the company to receive the full financing intended with the exercise of warrants, the Board, with authorization from the 2018 Annual General Meeting, has decided on a directed share issue of 326.451 shares, corresponding to approx. SEK 0,7 million, to Wilhelm Risberg who has been consideration-free guarantee subscriber in the warrant exercise. Initiator Pharma is provided with approx. SEK 12.7 million before issue costs as a result of the warrant exercise and the directed share issue.
Initiator Pharma tillförs cirka 12,7 MSEK genom optionsinlösen och riktad nyemission
Den 1 november 2018 avslutades nyttjandeperioden för Initiator Pharma A/S (“Initiator Pharma”) teckningsoptioner av serie TO 1. Totalt nyttjades 5 462 843 teckningsoptioner av serie TO 1, vilket innebär en teckningsgrad om cirka 94,4 procent. För att bolaget ska erhålla den fulla finansieringen som avsetts med teckningsoptionsnyttjande har styrelsen, med stöd av bemyndigande från årsstämman, beslutat om en riktad nyemission om 326 451aktier, motsvarande cirka 0,7 MSEK, till Wilhelm Risberg som agerat vederlagsfri garantiåtagare i optionsinlösen. Initiator Pharma tillförs genom nyttjandet av teckningsoptioner av serie TO 1 samt genom den riktade nyemissionen således totalt cirka 12,7 MSEK före emissionskostnader.